GlassScriptPhysician profile
Mathews Lal George
NPI 1902957244
$6,665.77
in general payments reported to CMS, 2019-2025
25 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.49 · 2020: $388 · 2021: $343 · 2022: $1,405 · 2023: $786 · 2024: $1,732 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Consulting Fee: $1,720 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.45 |
| Consulting Fee | $1,720.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $2,680.00 | 2022-2025 | Braftovi |
| Partner Therapeutics, INC. | $1,000.00 | 2025 | Bizengri |
| Astrazeneca Pharmaceuticals LP | $544.80 | 2020-2025 | Calquence |
| Daiichi Sankyo INC. | $374.99 | 2020-2023 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $302.08 | 2021-2023 | Imbruvica |
| Incyte Corporation | $225.64 | 2021-2025 | Jakafi |
| Pfizer INC. | $162.57 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.91 | 2020 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2024 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Stemline Therapeutics INC. | $124.99 | 2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $124.99 | 2024 | Tavalisse, Rezlidhia |
| Exelixis INC. | $122.07 | 2024 | Cabometyx |
| Immunocore Limited | $105.99 | 2024 | Kimmtrak |
| Gilead Sciences, INC. | $103.10 | 2024 | Trodelvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $97.47 | 2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $83.99 | 2023 | Fotivda |
| Puma Biotechnology, INC. | $46.54 | 2022-2023 | |
| Amgen INC. | $37.68 | 2019-2022 | |
| Celgene Corporation | $30.62 | 2023 | Sprycel |
| Myovant Sciences INC. | $29.23 | 2021 | |
| Novocure INC. | $23.73 | 2023 | Optune |
| Sun Pharmaceutical Industries INC. | $18.37 | 2023 | Odomzo, Yonsa |
| Cti Biopharma Corp. | $14.04 | 2022 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathews George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.